Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in Metastatic Renal Cell Carcinoma
NCT00515697Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Primary completion
- May 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in renal cell carcinoma (RCC), sponsored by Eli Lilly and Company. Started Nov 2007; status: completed.
02
Drugs
ramucirumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00515697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515697.